SCHEMBL2877924

SCHEMBL2877924

Clc1ccc(-c2n[nH]cc2Cl)s1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 1/20 0.32
PTGS1 P23219 3/20 0.32
PTGS2 P35354 3/20 0.32
HSD17B1 P14061 5/20 0.32
HSD17B2 P37059 4/20 0.32
PDGFRB P09619 1/20 0.32
PDGFRA P16234 1/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KDM4E B2RXH2 1/20 0.31
KDM1A O60341 1/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11627081 0.81 TP53 (0.40) CYP2A6L3MBTL1NPSR1PTGS1PTGS2
SCHEMBL8913905 0.78 NPSR1 (0.35) CYP2A6L3MBTL1NPSR1TSHRPTGS1
SCHEMBL2052721 0.75 CYP2A6 (0.41) CYP2A6L3MBTL1NPSR1TSHRHSD17B1
SCHEMBL9392560 0.73 ABL1 (0.33)
SCHEMBL2877926 0.72 ADORA2A (0.42) L3MBTL1ALDH1A1KMT2AMEN1MAPT
SCHEMBL8912243 0.71 NPSR1 (0.36) L3MBTL1NPSR1ALDH1A1KMT2AMEN1
SCHEMBL2049976 0.71 HSD17B1 (0.39) CYP2A6L3MBTL1HSD17B1HSD17B2PDGFRB
SCHEMBL9193008 0.68 CYP2A6 (0.50) CYP2A6L3MBTL1NPSR1TSHRHSD17B1
SCHEMBL2053083 0.68 CYP2A6 (0.40) CYP2A6L3MBTL1NPSR1TSHRHSD17B1
SCHEMBL1991512 0.65 HPGD (0.52) CYP2A6L3MBTL1NPSR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324216-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2012-12-04 US disclosed
US-7842693-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2010-11-30 US disclosed
US-20100240618-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2010-09-23 US disclosed
CN-1867336-B 1-aryl-4-substituted piperazines derivatives and pharmaceutical use thereof CHEMOCENTRYX INC 2010-05-12 CN disclosed
CN-100542534-C Substituted piperazines CHEMOCENTRYX INC (US) 2009-09-23 CN disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 US disclosed
EP-1531822-B1 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS CHEMOCENTRYX INC (US) 2009-08-05 EP disclosed
EP-1691810-A4 SUBSTITUTED PIPERAZINES CHEMOCENTRYX INC (US) 2009-07-01 EP disclosed
US-7449576-B1 potent antagonists of the CCR1 receptor; inflammation; (5-Chloro-2-piperazin-1-yl-phenyl)-phenyl-methanone CHEMOCENTRYX, INC. (US) 2008-11-11 US disclosed
US-20080261987-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2008-10-23 US disclosed
US-7157464-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2007-01-02 US disclosed
CN-1867336-A 1-aryl-4-substituted piperazines derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders CHEMOCENTRYX INC (US) 2006-11-22 CN disclosed
EP-1691810-A1 SUBSTITUTED PIPERAZINES ChemoCentryx Inc (US) 2006-08-23 EP disclosed
US-20060106218-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2006-05-18 US disclosed
US-20050256130-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2005-11-17 US disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 WO disclosed
EP-1531822-A1 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS Chemocentryx, Inc. (US) 2005-05-25 EP disclosed
US-20040162282-A1 Substituted piperazines CHEMOCENTRYX, INC. 2004-08-19 US disclosed
US-20040082571-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2004-04-29 US disclosed
WO-2003105853-A1 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS CHEMOCENTRYX, INC. (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261987-A1 SUBSTITUTED PIPERAZINES CCR1, CCR3, CCRL2 CYP2A6 2664/4885L3MBTL1 1517/4885NPSR1 469/4885
US-20040082571-A1 Substituted piperazines CCR1, CCR3, CCRL2 CYP2A6 2664/4885L3MBTL1 1517/4885NPSR1 469/4885
US-20060106218-A1 Substituted piperazines CCR1, CCR3, CCRL2 CYP2A6 2245/4885L3MBTL1 1589/4885NPSR1 380/4885
US-20050256130-A1 Substituted piperazines CCR1, CCR3, CCRL2 CYP2A6 2245/4885L3MBTL1 1589/4885NPSR1 380/4885
US-20040162282-A1 Substituted piperazines CCR1, CCR3, CCRL2 CYP2A6 2664/4885L3MBTL1 1517/4885NPSR1 469/4885
US-20100240618-A1 SUBSTITUTED PIPERAZINES CCR1, CCR3, CCRL2 CYP2A6 2245/4885L3MBTL1 1589/4885NPSR1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.